Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Express Scripts
US Department of Justice
US Army
Deloitte
AstraZeneca
Federal Trade Commission
Baxter
Johnson and Johnson
McKesson

Generated: February 20, 2018

DrugPatentWatch Database Preview

Claims for Patent: 8,324,189

« Back to Dashboard

Summary for Patent: 8,324,189
Title:Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases
Abstract: A method of intravenously administering a bisphosphonate to a patient in need of bisphosphonate treatment comprising intravenously administering 4 mg of 2-(imidazol-1yl)-1-hydroxyethane-1,1-diphosphonic acid (zoledronic acid) or a pharmaceutically acceptable salt thereof over a period of 15 minutes to a patient in need of said treatment.
Inventor(s): Galli; Bruno (Seltisberg, CH), Schran; Horst F (Morristown, NJ), Seaman; John J (New Hope, PA)
Assignee: Novartis Pharmaceuticals Corporation (East Hanover, NJ)
Application Number:11/594,410
Patent Claims: 1. A method of treatment of bone metabolism diseases, said method comprising intravenous administration of 4 mg of 2-(imidazol-1yl)-1-hydroxyethane-1,1-diphosphonic acid or a pharmaceutically acceptable salt thereof in an infusion solution volume of from about 5 up to about 200 ml over a period of 15 minutes to a patient in need of said treatment, wherein said intravenous administration improves renal safety.

2. The method according to claim 1, wherein said bone metabolism disease is tumour induced hypercalcemia.

3. The method according to claim 1, wherein said infusion volume is from about 50 to about 100 ml.

4. The method according to claim 1, wherein said infusion volume is about 100 ml.

5. The method according to claim 1, wherein the 2(imidazol-1yl)-1-hydroxyethane-1,1-diphosphonic acid is in the form of a pharmaceutically acceptable salt having one acidic hydrogen and one pharmaceutically acceptable cation in each of the phosphonic acid groups.

6. The method according to claim 5, wherein said pharmaceutically acceptable cation is sodium.

7. A method of treatment of bone metastases, said method comprising intravenous administration of 4 mg of 2-(imidazol-1yl)-1-hydroxyethane-1,1-diphosphonic acid or a pharmaceutically acceptable salt thereof in an infusion solution volume of from about 5 up to about 200 ml over a period of 15 minutes to a patient in need of said treatment, wherein said intravenous administration improves renal safety.

8. The method according to claim 7, wherein said infusion volume is from about 50 to about 100 ml.

9. The method according to claim 7, wherein said infusion volume is about 100 ml.

10. The method according to claim 7, wherein the 2-(imidazol-1yl)-1-hydroxyethane-1,1-diphosphonic acid is in the form of a pharmaceutically acceptable salt having one acidic hydrogen and one pharmaceutically acceptable cation in each of the phosphonic acid groups.

11. The method according to claim 10, wherein said pharmaceutically acceptable cation is sodium.

12. A method of treatment of multiple myeloma, said method comprising intravenous administration of 4 mg of 2-(imidazol-1yl)-1-hydroxyethane-1,1-diphosphonic acid or a pharmaceutically acceptable salt thereof in an infusion solution volume of from about 5 up to about 200 ml over a period of 15 minutes to a patient in need of said treatment, wherein the intravenous administration improves renal safety.

13. The method according to claim 12, wherein said infusion volume is from about 50 to abut 100 ml.

14. The method according to claim 12, wherein said infusion volume is about 100 ml.

15. The method according to claim 12, wherein the 2-(imidazol-1yl)-1-hydroxyethane-1,1-diphosphonic acid is in the form of a pharmaceutically acceptable salt having one acidic hydrogen and one pharmaceutically acceptable cation in each of the phosphonic acid groups.

16. The method according to claim 15, wherein said pharmaceutically acceptable cation is sodium.

17. A method of treatment of bone metabolism diseases, said method comprising intravenous administration of 4 mg of 2-(imidazol-1yl)-1-hydroxyethane-1,1-diphosphonic acid or a pharmaceutically acceptable salt thereof in an infusion solution volume of from about 5 up to about 200 ml over a period of 15 minutes to a patient in need of said treatment, wherein said intravenous administration reduces incidence of renal toxicity.

18. The method according to claim 17, wherein said bone metabolism disease is tumour induced hypercalcemia.

19. The method according to claim 17, wherein said infusion volume is from about 50 to about 100 ml.

20. The method according to claim 17, wherein said infusion volume is about 100 ml.

21. The method according to claim 17, wherein the 2(imidazol-1yl)-1-hydroxyethane-1,1-diphosphonic acid is in the form of a pharmaceutically acceptable salt having one acidic hydrogen and one pharmaceutically acceptable cation in each of the phosphonic acid groups.

22. The method according to claim 21, wherein said pharmaceutically acceptable cation is sodium.

23. A method of treatment of bone metastases, said method comprising intravenous administration of 4 mg of 2-(imidazol-1yl)-1-hydroxyethane-1,1-diphosphonic acid or a pharmaceutically acceptable salt thereof in an infusion solution volume of from about 5 up to about 200 ml over a period of 15 minutes to a patient in need of said treatment, wherein said intravenous administration reduces incidence of renal toxicity.

24. The method according to claim 23, wherein said infusion volume is from about 50 to about 100 ml.

25. The method according to claim 23, wherein said infusion volume is about 100 ml.

26. The method according to claim 23, wherein the 2-(imidazol-1yl)-1-hydroxyethane-1,1-diphosphonic acid is in the form of a pharmaceutically acceptable salt having one acidic hydrogen and one pharmaceutically acceptable cation in each of the phosphonic acid groups.

27. The method according to claim 26, wherein said pharmaceutically acceptable cation is sodium.

28. A method of treatment of multiple myeloma, said method comprising intravenous administration of 4 mg of 2-(imidazol-1yl)-1-hydroxyethane-1,1-diphosphonic acid or a pharmaceutically acceptable salt thereof in an infusion solution volume of from about 5 up to about 200 ml over a period of 15 minutes to a patient in need of said treatment, wherein the intravenous administration reduces incidence of renal toxicity.

29. The method according to claim 28 wherein said infusion volume is from about 50 to about 100 ml.

30. The method according to claim 28, wherein said infusion volume is about 100 ml.

31. The method according to claim 28, wherein the 2-(imidazol-1yl)-1-hydroxyethane-1,1-diphosphonic acid is in the form of a pharmaceutically acceptable salt having one acidic hydrogen and one pharmaceutically acceptable cation in each of the phosphonic acid groups.

32. The method according to claim 31, wherein said pharmaceutically acceptable cation is sodium.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Teva
Fish and Richardson
US Department of Justice
UBS
Chinese Patent Office
Merck
Argus Health
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot